Cargando…
Herpes Zoster in Patients Receiving JAK Inhibitors For Ulcerative Colitis: Mechanism, Epidemiology, Management, and Prevention
Increased risk of herpes zoster (HZ) has been observed in patients with immune-mediated diseases, including rheumatoid arthritis (RA), psoriasis (PsO), and inflammatory bowel disease; this risk can be further increased by the use of immunosuppressive therapy. One advancing modality of therapy for th...
Autor principal: | Colombel, Jean-Frédéric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6140435/ https://www.ncbi.nlm.nih.gov/pubmed/29788127 http://dx.doi.org/10.1093/ibd/izy150 |
Ejemplares similares
-
Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2018) -
JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications
por: Agrawal, Manasi, et al.
Publicado: (2020) -
Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2022) -
JAK inhibitors and infections risk: focus on herpes
zoster
por: Sunzini, Flavia, et al.
Publicado: (2020) -
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib—Implications for Cardiovascular Risk and Patient Management
por: Sands, Bruce E, et al.
Publicado: (2020)